## Ketoprofen (lysinate)

MedChemExpress

®

Cat. No.:	HY-B0227A	0
CAS No.:	57469-78-0	
Molecular Formula:	C <sub>22</sub> H <sub>28</sub> N <sub>2</sub> O <sub>5</sub>	
Molecular Weight:	400.47	0
Target:	СОХ	Q
Pathway:	Immunology/Inflammation	H <sub>2</sub> NOH
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	NH <sub>2</sub>

BIOLOGICAL AC	ΓΙVΙΤΥ		
Description	Ketoprofen (RP-19583) lysinate is a non-steroidal anti-inflammatory agent. Ketoprofen lysinate can inhibit the activity of cyclooxygenase with IC <sub>50</sub> values of 2 nM (COX-1) and 26 nM (COX-2). which is potential in the research of inflammation, immunology, and metabolic disease such as obesity <sup>[1][2][3]</sup> .		
IC <sub>50</sub> & Target	COX-1 2 nM (IC <sub>50</sub> )	COX-2 26 nM (IC <sub>50</sub> )	
In Vitro	Ketoprofen lysinate inhibits COX in LPS-stimulated monocytes isolated from human blood, with IC <sub>50</sub> values of 2 nM (COX-1) and 26 nM (COX-2) <sup>[1]</sup> . Ketoprofen lysinate (2.5 mg /mL, 3-24h) decreases the mRNA level of immune factors (TNFα, IL-8, SAA and COX-2) and PTGES in LPS-stimulated bovine mammary epithelial cells <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCR <sup>[3]</sup>		
	Cell Line:	LPS (0.2 $\mu$ g/mL)-stimulated bovine mammary epithelial cells	
	Concentration:	2.5 mg /mL	
	Incubation Time:	3, 6, 24 h	
	Result:	Decreased the mRNA level of TNF $\alpha$ , IL-8, SAA, COX-2 and PTGES.	
In Vivo	Ketoprofen lysinate (Oral administration, 10 mg/kg, three times a week for 10 weeks, HFD-induced obese C57BL/6 mice) decreases in relative body weight (15.41%), the iWAT mass (approximately 41%), and leptin (58.68%) and resistin (12.88%) <sup>[2]</sup> . Ketoprofen lysinate (50 mg/kg, LPS-treated dairy cows) lowers the increase of somatic cell count (SCC), serum albumin (SA), IgG and lactate dehydrogenase (LDH) activity in milk induced by LPS <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	· · · · · · · · · · · · · · · · · · ·		
	Animal Model:	HFD-induced obese C57BL/6 mice <sup>[2]</sup>	
	Dosage:	10 mg/kg	

Administration:	Oral administration, three times a week for 10 weeks
Result:	Decreased in relative body weight, the iWAT mass, and the level of leptin and resistin
Animal Model:	LPS (0.2 µg/mL)-treated dairy cows <sup>[3]</sup>
Dosage:	50 mg/kg
Administration:	Injection (Milk samples were taken every 30 min until 6 and 9 h)
Result:	Lowered the increase of somatic cell count (SCC), serum albumin (SA), IgG and lactate dehydrogenase (LDH) activity in milk.

## **CUSTOMER VALIDATION**

- Chemosphere. 2019 Jun;225:378-387.
- Eur J Pharm Sci. 2023 Jul 30;189:106550.
- J Neurotrauma. 2022 Sep 15.

See more customer validations on www.MedChemExpress.com

## REFERENCES

[1]. Palomer A, et al. Structure-based design of cyclooxygenase-2 selectivity into ketoprofen. Bioorg Med Chem Lett. 2002 Feb 25;12(4):533-7.

[2]. NamHyeon Kang Ketoprofen alleviates diet-induced obesity and promotes white fat browning in mice via the activation of COX-2 through mTORC1-p38 signaling pathway. Pflugers Arch. 2020 May;472(5):583-596.

[3]. Denisa Dan, et al. Ketoprofen affects the mammary immune response in dairy cows in vivo and in vitro. J Dairy Sci. 2018 Dec;101(12):11321-11329.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA